Alternative technique for reducing compound waste during intravitreal injections;Técnica alternativa para reduzir a perda de medicação durante injeção intravítrea

Arquivos Brasileiros de Oftalmologia

Volumn 72, Issue 5, 2009, Pages 641-644

  Ribeiro, Jefferson Augusto Santana ^a   Messias, André ^a   Scott, Ingrid U ^b   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis inhibitors; Drug administration routes; Injections; Macular degeneration; Ophthalmologic surgical procedures; Retinal diseases; Vitreous body

Indexed keywords

EID: 74249097809     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492009000500008     Document Type: Article

References (10)

1. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, et al. Evolving guidelines for intravitreous injections. Retina. 2004;24(5): S3-19. Comment in: Retina. 2005;25(7):949-50; author reply 950.
2. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46(10):3845-9.
3. Jaissle GB, Szurman P, Bartz-Schmidt KU; German Retina Society; German Society of Ophthalmology; German Professional Association of Ophthalmologists. [Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)]. Klin Monatsbl Augenheilkd. 2005;222(5):390-5. German.
4. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27(2):141-9.
5. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006; 47(10):4569-78.
6. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol. 2007;91(9):1177-82.
7. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-9. Comment in: Br J Ophthalmol. 2006;90(11):1333-4; Br J Ophthalmol. 2006;90(11):1440.
8. Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008;9(3):499-508.
9. Novartis. Lucentis [bula on Internet]. Switzerland: Novartis. [cited 2009 Jan 12]. Available from: http://www.medicinanet.com.br/bula/3194/lucentis.htm.
10. Souza CR, Zanetti ML. Administração de. insulina: uma abordagem fundamental na educação em diabetes. Rev Esc Enferm USP 2000;34(3):264-70.